Aidite (301580.SZ): As of the end of 2023, the proportion of the R&D team reached 14.64%, and R&D innovation investment has been increasing year by year.

Gelonghui Finance · Oct 14 04:25

Gelonghui October 14th | Edite (301580.SZ) stated on the investor interaction platform that the company has been shortlisted in the sixth batch of national specialized, special and new "little giant" enterprise public announcement list, and was officially announced in early September 2024. The company focuses on casting expertise, strengthening industrial support, and winning the market through innovation. By the end of 2023, the proportion of research and development team reached 14.64%, with annual increase in research and development innovation investment. After more than 10 years of technological accumulation and product iteration, since 2021, the company has successively won the first prize of Beijing Science and Technology Award, the Geneva Invention Gold Award, and other honors, obtaining the approval of the national key research and development plan "Diagnostic and Therapeutic Equipment and Biomedical Materials" key special project, and collaborating with multiple universities to launch national key research and development projects. With solid technology, products, and risk resistance capabilities, the company has passed the critical point of survival of small and medium-sized enterprises and entered a relatively stable development stage.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more

爱迪特(301580.SZ)：截止2023年底，研发团队占比达14.64%，研发创新投入逐年提升

Aidite (301580.SZ): As of the end of 2023, the proportion of the R&D team reached 14.64%, and R&D innovation investment has been increasing year by year.

Risk Disclaimer

Statement